HER2 Biology, Detection, and Clinical Implications

被引:15
作者
Gutierrez, Carolina [1 ]
Schiff, Rachel [2 ]
机构
[1] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[2] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA
关键词
IN-SITU HYBRIDIZATION; METASTATIC BREAST-CANCER; ESTROGEN-RECEPTOR; ADJUVANT CHEMOTHERAPY; GUIDELINE RECOMMENDATIONS; MOLECULAR PORTRAITS; GENE AMPLIFICATION; PROTEIN EXPRESSION; AMERICAN-SOCIETY; TRASTUZUMAB;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-HER2 is a membrane tyrosine kinase and oncogene that is overexpressed and gene amplified in about 20% of breast cancers. When activated it provides the cell with potent proliferative and antiapoptosis signals and it is the major driver of tumor development and progression for this subset of breast cancer. When shown to be overexpressed or amplified by appropriate methods, HER2 is a valuable treatment target. Objectives.-To review the basic biology of the HER2 signaling network, to discuss various approved methods for its detection in clinical specimens, and to describe the impressive results of therapies targeting HER2. Data Sources.-Selected literature searchable on PubMed as well as older studies revealed by the literature review were reviewed. Conclusion.-HER2 is an important member of a complex signaling network and when gene amplified, it results in an aggressive subtype of breast cancer. Patients with tumors found to overexpress HER2 protein or to be amplified for the gene are candidates for therapy that significantly reduces mortality. (Arch Pathol Lab Med. 2011;135:55-62)
引用
收藏
页码:55 / 62
页数:8
相关论文
共 77 条
[21]   Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial [J].
Joensuu, Heikki ;
Bono, Petri ;
Kataja, Vesa ;
Alanko, Tuomo ;
Kokko, Riitta ;
Asola, Raija ;
Utriainen, Tapio ;
Turpeenniemi-Hujanen, Taina ;
Jyrkkio, Sirkku ;
Moykkynen, Kari ;
Helle, Leena ;
Ingalsuo, Seija ;
Pajunen, Marjo ;
Huusko, Mauri ;
Salminen, Tapio ;
Auvinen, Paivi ;
Leinonen, Hannu ;
Leinonen, Mika ;
Isola, Jorma ;
Kellokumpu-Lehtinen, Pirkko-Liisa .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5685-5692
[22]   Evolving novel anti-HER2 strategies [J].
Jones, Kellie L. ;
Buzdar, Aman U. .
LANCET ONCOLOGY, 2009, 10 (12) :1179-1187
[23]   ERBB2 AMPLIFICATION IN BREAST-CANCER ANALYZED BY FLUORESCENCE INSITU HYBRIDIZATION [J].
KALLIONIEMI, OP ;
KALLIONIEMI, A ;
KURISU, W ;
THOR, A ;
CHEN, LC ;
SMITH, HS ;
WALDMAN, FM ;
PINKEL, D ;
GRAY, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (12) :5321-5325
[24]   Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study [J].
Kaufman, Bella ;
Mackey, John R. ;
Clemens, Michael R. ;
Bapsy, Poonamalle P. ;
Vaid, Ashok ;
Wardley, Andrew ;
Tjulandin, Sergei ;
Jahn, Michaela ;
Lehle, Michaela ;
Feyereislova, Andrea ;
Revil, Cedric ;
Jones, Alison .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5529-5537
[25]   AMPLIFICATION OF A NOVEL V-ERBB-RELATED GENE IN A HUMAN MAMMARY-CARCINOMA [J].
KING, CR ;
KRAUS, MH ;
AARONSON, SA .
SCIENCE, 1985, 229 (4717) :974-976
[26]  
KONECNY G, 2003, JNCI-J NATL CANCER I, V95, P42
[27]   HER2 status in breast cancer -: an example of pharmacogenetic testing [J].
Kroese, Mark ;
Zimmern, Ron L. ;
Pinder, Sarah E. .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2007, 100 (07) :326-329
[28]   Chromogenic and fluorescent in situ hybridization in breast cancer [J].
Lambros, Maryou B. K. ;
Natrajan, Rachael ;
Reis-Filho, Jorge S. .
HUMAN PATHOLOGY, 2007, 38 (08) :1105-1122
[29]   The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast [J].
Latta, EK ;
Tjan, S ;
Parkes, RK ;
O'Malley, FP .
MODERN PATHOLOGY, 2002, 15 (12) :1318-1325
[30]  
LIPTON A, 2010, CANCER IN PRESS